Company news
Bayer Ag (XETR:BAYN) news
Bayer Ag news releases on 6ix. Latest, Oct 2, 2026: Bayer to Invest $2.2 Billion in a New Manufacturing Site in Ohio
Press releases & updates
Bayer to Invest $2.2 Billion in a New Manufacturing Site in Ohio
October 2, 2026
Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States
October 2, 2026
Bayer : appoints Dr. Christoph Koenen, MD, as Chief Medical Officer
October 1, 2026
Bayer : BlueRock Therapeutics’ investigational cell therapy lemiretprocel (OpCT-001) for primary photoreceptor diseases granted orphan drug designations by FDA and EMA
September 30, 2026
MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option
September 29, 2026
U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer
September 28, 2026
Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
September 17, 2026
Apollo Funds Complete €3 Billion Capital Solution for Bayer
September 16, 2026
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
September 10, 2026
U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
September 9, 2026
Bayer and Neste Close Commercial Agreement to Jointly Scale newgold® Winter Canola for Biofuels Production
September 9, 2026
BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION
September 9, 2026
Bayer : initiates Phase II study of investigational GIRK4 inhibitor in patients with atrial fibrillation
September 9, 2026
First licensed treatment now available for condition behind the UK’s leading cause of horse euthanasia
September 8, 2026
Bayer Advances Combined Seed and Crop Protection Pipeline and Enters Phase of Blockbuster Launches
September 3, 2026
Bayer : Finerenone slowed kidney function decline and reduced kidney-cardiovascular risk versus placebo in patients with hypertensive nephropathy
August 31, 2026
Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026
August 30, 2026
Bayer : AskBio Presents Baseline Characteristics from Phase 2 Heart Failure Gene Therapy Trial of Umiposgene Parvec (AB-1002) at European Society of Cardiology Congress
August 29, 2026
Bayer : sevabertinib approved in Japan for patients with HER2-mutant non-small cell lung cancer
August 24, 2026
Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026
August 20, 2026
Bayer : Aflibercept 8 mg application for macular edema following retinal vein occlusion accepted for review in China
August 13, 2026
Bayer : operationally on track, decisive progress on strategic priorities
August 4, 2026
Bayer : submits application for next indication of Kerendia in China
July 30, 2026
New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters
July 23, 2026
Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials
July 17, 2026
European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU
July 17, 2026
Bayer : signs licensing agreement with RAGT and begins broad hybrid wheat commercialization by early 2030s
July 15, 2026
Bayer : Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farming
July 14, 2026
Bayer Aktiengesellschaft: Bayer secures 3.0 billion euros to improve capital structure
July 10, 2026
The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical Trials
July 7, 2026
The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical Trials
July 7, 2026
Bayer Group to Consolidate U.S. Glyphosate Business Into Distinct Entity Operating as Ruveon
July 1, 2026
Bayer Welcomes Kacy Perry as New Country Division Head for Crop Science Canada
June 18, 2026
Bayer : Federal judge remands Monsanto class settlement case back to Missouri State Court
June 17, 2026
Natur Tec India and Bayer to Develop Compostable Seedling Cups
June 16, 2026
Bayer : low-dose MRI contrast agent approved in U.S.
June 15, 2026
Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions
June 15, 2026
Bayer : European Medicines Agency confirms asundexian marketing authorization application for assessment in secondary prevention of ischemic stroke
June 10, 2026
Bayer : Announces Advancement in Cardiovascular Health Assessment with Saudi Heart Association's recent publication on Early Detection of Subclinical Atherosclerosis in Clinical Practice
June 9, 2026
Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth
June 8, 2026
Bayer : finerenone significantly reduced kidney function decline and a composite of cardiovascular-kidney outcomes versus placebo in patients with non-diabetic chronic kidney disease
June 5, 2026
Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026
June 2, 2026
ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
May 30, 2026
Bayer : Kerendia™ approved in China for new indication in adult patients with heart failure with LVEF ≥40%
May 22, 2026
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
May 21, 2026
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
May 21, 2026
Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
May 21, 2026
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
May 19, 2026
Bayer : FDA grants sevabertinib Priority Review as a first-line treatment for patients with HER2-mutant non-small cell lung cancer
May 18, 2026
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
May 15, 2026